Американское общество гирудотерапии

Narrowband ultraviolet B phototherapy in children with moderate-to-severe eczema: a comparative cohort study

Comparative study published in The British journal of dermatology (2014)

Последнее обновление: June 18, 2026Рецензент: ASH Editorial Board
Research article — evidence reviewArticle reference
Evidence: Observational studyКлинические исследованияDarn S et al. · The British journal of dermatology, 2014

Abstract

BACKGROUND: There is only retrospective evidence for the efficacy of narrowband ultraviolet B (NB-UVB) in children with eczema. OBJECTIVES: To measure the difference in means for objective scores [Six Area Six Sign Atopic Dermatitis score (SASSAD), percentage surface area] and quality-of-life scores, between patients treated with NB-UVB and unexposed cohorts at the end of treatment, and 3 and 6 months post-treatment. METHODS: Twenty-nine children aged 3-16 years for whom NB-UVB was indicated, were scored prospectively using SASSAD and percentage surface area involvement at baseline, at 12 weeks (end of treatment) and 3 and 6 months post-NB-UVB. Their scores were compared with those of unexposed children (n = 26) for whom NB-UVB phototherapy was indicated and offered, but who chose not to undertake treatment. RESULTS: There was a 61% reduction in mean SASSAD score in the NB-UVB cohort compared with an increase of 6% in the unexposed cohort. Mean SASSAD score for the NB-UVB cohort at the end of treatment was 11.6 vs. 24.8 for the unexposed; difference in means -13.2 [95% confidence interval (CI) -18.7 to -7.7, P < 0.0001]. Mean surface area involvement at the end of treatment was 11% for the NB-UVB cohort vs. 36% for the unexposed cohort; difference in means -25% (95% CI -34% to -16%, P < 0.0001). Subjective and quality-of-life scores showed significant difference between cohorts at the end of treatment (P < 0.05). Objective scores remained significantly lower than in the unexposed cohort 3 and 6 months after treatment. CONCLUSION: NB-UVB is clinically effective and improves quality of life in children with moderate-to-severe eczema. The effect is maintained for 6 months after treatment.

Abstract sourced from PubMed (NCBI) for the cited record. See the original publication for the authoritative version.

Publication typeComparative StudyEvaluation StudyJournal ArticleResearch Support, Non-U.S. Gov't
Indexed MeSH termsAdolescentChildChild, PreschoolEczemaFemaleHumansMaleProspective StudiesRemission InductionTreatment OutcomeUltraviolet Therapy

Резюме

There is only retrospective evidence for the efficacy of narrowband ultraviolet B (NB-UVB) in children with eczema.

Почему это важно для гирудотерапии

This study evaluated the clinical effectiveness of narrowband ultraviolet B (NB-UVB) phototherapy in children aged 3–16 with moderate-to-severe eczema, measuring objective severity scores (SASSAD, surface area involvement) and quality-of-life outcomes at treatment end and at 3 and 6 months post-treatment. The NB-UVB cohort showed significant improvements compared to an unexposed cohort, with effects maintained at 6 months. This article has no connection to leeches, hirudotherapy, hirudin, or the leech secretome; there is no defensible relevance to ASH's domain. The study concerns dermatological phototherapy for childhood eczema, and no anticoagulant, thrombin inhibitor, or leech-related content appears in the abstract.

Цитирование

Narrowband ultraviolet B phototherapy in children with moderate-to-severe eczema: a comparative cohort study

Darn S et al. · The British journal of dermatology, 2014

Связанный клинический контекст

Узнайте, как это исследование связано с клинической практикой

Добавлено в библиотеку ASH: May 27, 2026 · Последнее обновление сайта: June 18, 2026

Этот сайт предоставляет образовательную информацию и не является медицинской консультацией, диагнозом или рекомендацией по лечению. Гирудотерапия сопряжена с клинически значимыми рисками и должна проводиться только квалифицированными клиницистами в рамках институционально утверждённых протоколов. Разрешение FDA 510(k) для медицинских пиявок ограничено определёнными показаниями; обсуждения исследовательского и нелицензионного применения отмечены соответствующим образом. Для индивидуальных медицинских рекомендаций обратитесь к квалифицированному медицинскому специалисту.